Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections

Infectious Diseases and Therapy
Jordan R SmithM J Rybak

Abstract

Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections (ABSSSIs). It is active against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and minimum inhibitory concentrations (MICs) are consistently <0.125 µg/ml, much lower than most other anti-MRSA agents. Dalbavancin possesses an extended half-life of over 1 week, allowing an initial dose of 1000 mg followed by 500 mg 1 week later to complete a course of therapy for ABSSSI. It is approximately 95% protein bound and is widely distributed throughout the body, achieving concentrations similar to plasma levels in numerous tissues. Against MRSA, dalbavancin is 4-8 times more potent than vancomycin in vitro, and limited data suggest it possesses activity against MRSA with reduced susceptibility to vancomycin such as hVISA and VISA. Dalbavancin also possesses in vitro activity against streptococci and enterococci, although activity against vancomycin-resistant enterococci is lacking. In phase 3 ABSSSI studies, dalbavancin demonstrated similar activity to vancomycin and provides a more convenient dosing regimen. Limited phase 2 da...Continue Reading

Associated Clinical Trials

References

Aug 1, 1993·The Journal of Antibiotics·R Nagarajan
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Oct 30, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elyse SeltzerUNKNOWN Dalbavancin Skin and Soft-Tissue Infection Study Group
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Anton LeightonEllen Kelly
Jun 17, 2004·Journal of Clinical Pharmacology·Steven BarriereJoel Morganroth
Jan 26, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Issam RaadElyse Seltzer
Mar 8, 2005·The Journal of Antimicrobial Chemotherapy·Adriano Malabarba, Beth P Goldstein
Mar 8, 2005·The Journal of Antimicrobial Chemotherapy·Mary Beth DorrTimothy J Henkel
Mar 8, 2005·The Journal of Antimicrobial Chemotherapy·Marco CavaleriMartin Stogniew
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis E JaureguiWilliam O'Riordan
Oct 22, 2005·Journal of Clinical Pharmacology·Mary Buckwalter, James A Dowell
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert C Moellering
May 16, 2006·International Journal of Antimicrobial Agents·David M JohnsonRonald N Jones
Aug 8, 2006·The Journal of Antimicrobial Chemotherapy·Karen E BowkerAlasdair P MacGowan
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·David Andes, William A Craig
Apr 28, 2007·Expert Opinion on Investigational Drugs·Aryun KimDavid P Nicolau
Jul 17, 2007·The Journal of Antimicrobial Chemotherapy·David P NicolauJames A Dowell
Feb 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dawn M SievertJeffrey C Hageman
Jul 18, 2008·Journal of Clinical Pharmacology·James A DowellBharat Damle
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine
Mar 26, 2009·Journal of Clinical Pharmacology·Thomas MarburyMary Buckwalter
Mar 1, 2011·Diagnostic Microbiology and Infectious Disease·James A KarlowskyUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA)
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Jan 30, 2013·Diagnostic Microbiology and Infectious Disease·Ronald N JonesRobert K Flamm
Feb 26, 2013·Diagnostic Microbiology and Infectious Disease·Ronald N JonesHelio S Sader
Apr 10, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Benjamin P HowdenTimothy P Stinear
Nov 26, 2013·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jessica K OrtwineMichael J Rybak
Apr 18, 2014·The New England Journal of Medicine·Flávia RossiCesar A Arias
May 9, 2014·Chemistry : a European Journal·Juan TreviñoMaría J Hernáiz
Jun 5, 2014·The New England Journal of Medicine·Helen W BoucherMichael W Dunne
Jan 7, 2015·Antimicrobial Agents and Chemotherapy·Michael W DunneJames Baldassarre
Mar 1, 2015·Diagnostic Microbiology and Infectious Disease·Ronald N JonesRodrigo E Mendes
May 20, 2015·Antimicrobial Agents and Chemotherapy·Sandra P McCurdyMichael W Dunne

❮ Previous
Next ❯

Citations

Aug 27, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S Esposito, S Bianchini
Mar 16, 2017·Expert Review of Clinical Pharmacology·Ronald G HallKenna D Payne
Sep 29, 2018·Surgical Infections·Donald E Fry
Dec 7, 2018·Current Opinion in Pediatrics·James B WoodC Buddy Creech
Dec 21, 2017·Expert Opinion on Drug Metabolism & Toxicology·M GalluzzoM Talamonti
Sep 25, 2016·Cold Spring Harbor Perspectives in Medicine·Daina ZengJohn L Pace
Apr 1, 2020·Expert Review of Anti-infective Therapy·Alex SorianoFederico Pea
Jun 20, 2017·Journal of Clinical Pharmacy and Therapeutics·J M SteeleB T Mogle
Jul 10, 2018·The Journal of Antimicrobial Chemotherapy·Michael A PfallerHelio S Sader
Jan 17, 2020·Antibiotics·Charles H Chen, Timothy K Lu
May 16, 2019·Nature Reviews. Nephrology·Tina Z WangDavid P Calfee
Dec 19, 2020·The Journal of Antimicrobial Chemotherapy·Ka Lip ChewJeanette Teo
Jul 30, 2020·International Journal of Antimicrobial Agents·Emanuele Durante-MangoniNicola Coppola
Jan 7, 2021·Current Opinion in Infectious Diseases·Matteo BassettiDaniele R Giacobbe
Jan 5, 2021·Current Opinion in Infectious Diseases·Daniele R GiacobbeMatteo Bassetti
Apr 2, 2021·Therapeutics and Clinical Risk Management·Oriana SimonettiAnnamaria Offidani
Apr 13, 2021·The Journal of Antimicrobial Chemotherapy·Alix PantelJean-Philippe Lavigne
May 12, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Nur Najihah Izzati Mat RaniMohd Cairul Iqbal Mohd Amin
Mar 23, 2019·Microbiology Spectrum·Martin VestergaardHanne Ingmer
May 18, 2021·Frontiers in Molecular Biosciences·Lauren WalshR Paul Ross
Jul 3, 2021·Life·Roberto GiurazzaEmanuele Durante-Mangoni
Sep 27, 2021·Journal of Clinical Pharmacology·Dan F SmelterWarren E Rose
Nov 20, 2021·Medicinal Research Reviews·Vladimir VimbergGabriela B Novotná

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02127970

Software Mentioned

DISCOVER
hVISA
VISA

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.